Abstract
Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lymphomas, characterized by unfavorable prognosis and early relapse following conventional purine analog-based regimens. In this study, we report 2 patients with relapsed HCLv treated with ibrutinib. The first patient achieved a partial response following ibrutinib treatment and received the drug for 16 months, without severe adverse events. However, at disease progression venetoclax was not clinically active. The second patient discontinued the drug early due to intolerance. Ibrutinib was active in our patients with HCLv and deserve further investigations.
Keywords:
BTK; HCL; HCL variant; ibrutinib; venetoclax.
© 2020 John Wiley & Sons Ltd.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / adverse effects
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers
-
Biopsy
-
Female
-
Humans
-
Immunohistochemistry
-
Immunophenotyping
-
Leukemia, Hairy Cell / diagnosis*
-
Leukemia, Hairy Cell / drug therapy*
-
Leukemia, Hairy Cell / therapy
-
Middle Aged
-
Piperidines / administration & dosage
-
Piperidines / adverse effects
-
Piperidines / therapeutic use*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Retreatment
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Biomarkers
-
Piperidines
-
Protein Kinase Inhibitors
-
ibrutinib
-
Adenine